FDA Fast-Tracking Under Scrutiny Over Preterm Birth Drug
The agency’s accelerated approval program for certain drugs has come under intense scrutiny because some are on the market now despite limited evidence that they work.
Read Full Article »
Comment
Show comments
Hide Comments
